Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 38610074)

  • 21. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
    Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
    Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.
    Lamb YN
    Target Oncol; 2021 Sep; 16(5):687-695. PubMed ID: 34564820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
    Wang S; Cang S; Liu D
    J Hematol Oncol; 2016 Apr; 9():34. PubMed ID: 27071706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies.
    Ferro A; Marinato GM; Mulargiu C; Marino M; Pasello G; Guarneri V; Bonanno L
    Crit Rev Oncol Hematol; 2024 Apr; 196():104295. PubMed ID: 38382773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
    Wang S; Song Y; Yan F; Liu D
    Front Med; 2016 Dec; 10(4):383-388. PubMed ID: 27770386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osimertinib for the treatment of patients with
    Alsharedi M; Bukamur H; Elhamdani A
    Drugs Today (Barc); 2018 Jun; 54(6):369-379. PubMed ID: 29998228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
    Remon J; Steuer CE; Ramalingam SS; Felip E
    Ann Oncol; 2018 Jan; 29(suppl_1):i20-i27. PubMed ID: 29462255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
    Proto C; Lo Russo G; Corrao G; Ganzinelli M; Facchinetti F; Minari R; Tiseo M; Garassino MC
    Tumori; 2017 Jul; 103(4):325-337. PubMed ID: 28708233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance.
    Qu F; Zhou Y; Yu W
    Anticancer Drugs; 2022 Jan; 33(1):e76-e83. PubMed ID: 34520433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
    Soejima K; Yasuda H; Hirano T
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis.
    Yu Z; Xu F; Zou J
    Eur J Clin Pharmacol; 2024 Apr; 80(4):505-517. PubMed ID: 38300281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Pirker R
    Curr Opin Oncol; 2016 Mar; 28(2):115-21. PubMed ID: 26720671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis.
    Guo L; Zhou G; Huang M; Tang K; Xu J; Chen J
    Clin Respir J; 2024 Apr; 18(4):e13748. PubMed ID: 38584122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer.
    Zeng Y; Yu D; Tian W; Wu F
    Curr Opin Oncol; 2022 Jan; 34(1):54-65. PubMed ID: 34669648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
    Leonetti A; Sharma S; Minari R; Perego P; Giovannetti E; Tiseo M
    Br J Cancer; 2019 Oct; 121(9):725-737. PubMed ID: 31564718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting EGFR
    Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
    Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR degraders in non-small-cell lung cancer: Breakthrough and unresolved issue.
    Shen J; Chen L; Liu J; Li A; Zheng L; Chen S; Li Y
    Chem Biol Drug Des; 2024 Apr; 103(4):e14517. PubMed ID: 38610074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.
    Shaikh M; Shinde Y; Pawara R; Noolvi M; Surana S; Ahmad I; Patel H
    J Med Chem; 2022 Jan; 65(2):1008-1046. PubMed ID: 34323489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.